Maraviroc: a review of its use in HIV infection and beyond
SM Woollard, GD Kanmogne - Drug design, development and …, 2015 - Taylor & Francis
The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope
glycoprotein gp120 to the CD4 receptor and/or coreceptors such as CC chemokine receptor …
glycoprotein gp120 to the CD4 receptor and/or coreceptors such as CC chemokine receptor …
Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence
Antiretroviral (ARV) therapy, comprising a backbone of two nucleos (t) ide reverse
transcriptase inhibitors (NRTI s) plus another ARV, is the recognized standard of care (SOC) …
transcriptase inhibitors (NRTI s) plus another ARV, is the recognized standard of care (SOC) …
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
HJ Stellbrink, E Le Fevre, A Carr, MS Saag… - Aids, 2016 - journals.lww.com
Objective: The aim of this study was to evaluate the efficacy of maraviroc along with
darunavir/ritonavir, all once daily, for the treatment of antiretroviral-naive HIV-1 infected …
darunavir/ritonavir, all once daily, for the treatment of antiretroviral-naive HIV-1 infected …
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir
TN Kakuda, A Brochot, FL Tomaka… - Journal of …, 2014 - academic.oup.com
The ability to dose antiretroviral agents once daily simplifies the often complex therapeutic
regimens required for the successful treatment of HIV infection. Thus, once-daily dosing can …
regimens required for the successful treatment of HIV infection. Thus, once-daily dosing can …
Antiretroviral regimens sparing agents from the nucleoside (tide) reverse transcriptase inhibitor class: a review of the recent literature
The nucleoside (tide) reverse transcriptase inhibitors (NRTIs) have traditionally been an
important 'back-bone'of an antiretroviral therapy (ART) regimen. However all agents have …
important 'back-bone'of an antiretroviral therapy (ART) regimen. However all agents have …
Two-drug treatment approaches in HIV: finally getting somewhere?
SG Kelly, AN Nyaku, BO Taiwo - Drugs, 2016 - Springer
The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-
related morbidity and mortality. Nevertheless, the benefits of ART are only realized through …
related morbidity and mortality. Nevertheless, the benefits of ART are only realized through …
[HTML][HTML] Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48 …
S Nozza, L Galli, A Antinori, S Chiappetta… - Clinical Microbiology …, 2015 - Elsevier
Non-conventional strategies with nucleoside/nucleotide reverse transcriptase inhibitor-
sparing regimens in antiretroviral naive human immunodeficiency virus (HIV)-infected …
sparing regimens in antiretroviral naive human immunodeficiency virus (HIV)-infected …
The I ntelence aNd pRezist a O nce AD ay S tudy (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV …
PJ Ruane, C Brinson, M Ramgopal, R Ryan… - HIV …, 2015 - Wiley Online Library
Objectives Following antiretroviral therapy failure, patients are often treated with a three‐
drug regimen that includes two nucleoside/tide reverse transcriptase inhibitors [N (t) RTIs] …
drug regimen that includes two nucleoside/tide reverse transcriptase inhibitors [N (t) RTIs] …
Efficacy and safety of once‐daily maraviroc plus ritonavir‐boosted darunavir in pretreated HIV‐infected patients in a real‐life setting
Objectives Nucleoside reverse transcriptase inhibitor (NRTI)‐sparing regimens may be
needed in patients with NRTI toxicity. Maraviroc (MVC) plus ritonavir‐boosted darunavir …
needed in patients with NRTI toxicity. Maraviroc (MVC) plus ritonavir‐boosted darunavir …
Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients …
MC Romero-Sánchez, AI Álvarez-Ríos, E Bernal-Morell… - Antiviral research, 2014 - Elsevier
Novel strategies are necessary to decrease inflammatory parameters in successfully treated
HIV-infected patients. Our aim was to evaluate the maintenance of viral suppression and …
HIV-infected patients. Our aim was to evaluate the maintenance of viral suppression and …